Pfizer Makes Accurin Deal BIND-ing
This article was originally published in Scrip
Executive Summary
You may also be interested in...
Pfizer Jumps At The Chance To Apply Bind’s Technology To Immuno-Oncology
Bind has agreed to sell all of its assets to Pfizer for $19.75m after filing for bankruptcy in May. An auction is scheduled for July 25 if other bidders come forward.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.